Phase 2 Study of Dabrafenib Plus Trametinib in Patients with BRAF V600E Mutant Metastatic NSCLC

Personalized therapy to further improve outcomes in Patients with BRAF Mutated mNSCLC

NSCLC is a heterogeneous set of diseases defined by oncogenic drivers

Brigatinib versus Crizotinib in ALK Inhibitor Naive Advanced ALK Positive NSCLC

Clinical implications of cardiotoxicity and pharmacokinetics of alectinib

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients

ALK Rearrangements in Lung Cancer

Phase II study of Lorlatinib in Patients with Anaplastic Lymphoma Kinase

Panel Discussion - ALESIA 5 year update and Optimal Sequencing of TKIs

No Topic

The Phase II Study of Unecritinib TQ B3101 monotherapy in the 1L treatment

Durability of Efficacy and Safety with Selpercatinib in Patients with RET Fusion

The efficacy and safety of Taletrectinib in patients with TKI naive

NVL 520 ROS TKI

RET MAP An International multi center study on clinicopathologic features

Capmatinib in MET exon 14 mutated advanced NSCLC updated results from the GEOMETRY

Tepotinib in asian patients with advanced NSCLC with MET exon 14 skipping

Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer

Safety and efficacy of Pralsetinib in RET fusion positive

RET fused NSCLC State of the art treatment of advanced disease

Panel Discussion - Management of ROS and RET positive NSCLC

Overview of the two indications of Entrectinib

Entrectinib in chinese patients with Locally advanced metastatic ROS1 fusion

Updated efficacy and safety of larotrectinib in patients with tropomyosin

Amivantamab in NSCLC patients with MET exon 14 askipping mutation

Final OS results and subgroup analysis of savolitinib in patients with MET exon 14

Panel Discussion - Case Discussion (NTRK/MET)

Closing Remarks

Phase 2 Study of Dabrafenib Plus Trametinib in Patients with BRAF V600E Mutant Metastatic NSCLC

Personalized therapy to further improve outcomes in Patients with BRAF Mutated mNSCLC

Brigatinib versus Crizotinib in ALK Inhibitor Naive Advanced ALK Positive NSCLC

Clinical implications of cardiotoxicity and pharmacokinetics of alectinib

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients

ALK Rearrangements in Lung Cancer

Phase II study of Lorlatinib in Patients with Anaplastic Lymphoma Kinase

Panel Discussion - ALESIA 5 year update and Optimal Sequencing of TKIs

The Phase II Study of Unecritinib TQ B3101 monotherapy in the 1L treatment

Durability of Efficacy and Safety with Selpercatinib in Patients with RET Fusion

The efficacy and safety of Taletrectinib in patients with TKI naive

NVL 520 ROS TKI

RET MAP An International multi center study on clinicopathologic features

Capmatinib in MET exon 14 mutated advanced NSCLC updated results from the GEOMETRY

Safety and efficacy of Pralsetinib in RET fusion positive

RET fused NSCLC State of the art treatment of advanced disease

Panel Discussion - Management of ROS and RET positive NSCLC

Updated efficacy and safety of larotrectinib in patients with tropomyosin

Final OS results and subgroup analysis of savolitinib in patients with MET exon 14

Panel Discussion - Case Discussion (NTRK/MET)